Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1997;75(3):177–189.

Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.

PMCID: PMC2486958  PMID: 9277004

Abstract

Inherited thrombophilias are common disorders with a worldwide distribution, including antithrombin, protein C, and protein S deficiencies as well as resistance to activated protein C. Increased understanding of these disorders suggests that thrombophilia can arise from interaction between defective genes and environmental factors. WHO and the international Society on Thrombosis and Haemostasis (ISTH) discussed the problems of inherited thrombophilia at a joint meeting held in Geneva on 6-8 November 1995. The present article reports on the various possibilities for controlling the disorder and makes a series of recommendations for diagnosis, treatment, and research into the condition.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiach M., Gandrille S., Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost. 1995 Jul;74(1):81–89. [PubMed] [Google Scholar]
  2. Ben-Tal O., Zivelin A., Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost. 1989 Feb 28;61(1):50–54. [PubMed] [Google Scholar]
  3. Castaman G., Ruggeri M., Burei F., Rodeghiero F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thromb Res. 1993 Feb 1;69(3):297–305. doi: 10.1016/0049-3848(93)90027-l. [DOI] [PubMed] [Google Scholar]
  4. Chowdhury V., Lane D. A., Mille B., Auberger K., Gandenberger-Bachem S., Pabinger I., Olds R. J., Thein S. L. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost. 1994 Aug;72(2):198–202. [PubMed] [Google Scholar]
  5. De Stefano V., Leone G., Mastrangelo S., Tripodi A., Rodeghiero F., Castaman G., Barbui T., Finazzi G., Bizzi B., Mannucci P. M. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994 Sep;72(3):352–358. [PubMed] [Google Scholar]
  6. De Stefano V., Mastrangelo S., Paciaroni K., Ireland H., Lane D. A., Scirpa P., Bizzi B., Leone G. Thrombotic risk during pregnancy and puerperium in women with APC-resistance--effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost. 1995 Aug;74(2):793–794. [PubMed] [Google Scholar]
  7. Demers C., Ginsberg J. S., Hirsh J., Henderson P., Blajchman M. A. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med. 1992 May 1;116(9):754–761. doi: 10.7326/0003-4819-116-9-754. [DOI] [PubMed] [Google Scholar]
  8. Engesser L., Kluft C., Briët E., Brommer E. J. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol. 1987 Nov;67(3):355–358. doi: 10.1111/j.1365-2141.1987.tb02357.x. [DOI] [PubMed] [Google Scholar]
  9. Falcon C. R., Cattaneo M., Panzeri D., Martinelli I., Mannucci P. M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994 Jul;14(7):1080–1083. doi: 10.1161/01.atv.14.7.1080. [DOI] [PubMed] [Google Scholar]
  10. Finazzi G., Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost. 1994 Jan;71(1):15–18. [PubMed] [Google Scholar]
  11. Finazzi G., Caccia R., Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost. 1987 Dec 18;58(4):1094–1094. [PubMed] [Google Scholar]
  12. Gandrille S., Borgel D., Eschwege-Gufflet V., Aillaud M., Dreyfus M., Matheron C., Gaussem P., Abgrall J. F., Jude B., Sie P. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood. 1995 Jan 1;85(1):130–138. [PubMed] [Google Scholar]
  13. Ginsberg J. S., Hirsh J. Anticoagulants during pregnancy. Annu Rev Med. 1989;40:79–86. doi: 10.1146/annurev.me.40.020189.000455. [DOI] [PubMed] [Google Scholar]
  14. Gladson C. L., Scharrer I., Hach V., Beck K. H., Griffin J. H. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988 Feb 25;59(1):18–22. [PubMed] [Google Scholar]
  15. Griffin J. H., Evatt B., Wideman C., Fernández J. A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993 Oct 1;82(7):1989–1993. [PubMed] [Google Scholar]
  16. Gómez E., Poort S. R., Bertina R. M., Reitsma P. H. Identification of eight point mutations in protein S deficiency type I--analysis of 15 pedigrees. Thromb Haemost. 1995 May;73(5):750–755. [PubMed] [Google Scholar]
  17. Haverkate F., Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995 Jan;73(1):151–161. [PubMed] [Google Scholar]
  18. Hayashi T., Nishioka J., Shigekiyo T., Saito S., Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994 Feb 1;83(3):683–690. [PubMed] [Google Scholar]
  19. Heijboer H., Brandjes D. P., Büller H. R., Sturk A., ten Cate J. W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990 Nov 29;323(22):1512–1516. doi: 10.1056/NEJM199011293232202. [DOI] [PubMed] [Google Scholar]
  20. Koster T., Blann A. D., Briët E., Vandenbroucke J. P., Rosendaal F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995 Jan 21;345(8943):152–155. doi: 10.1016/s0140-6736(95)90166-3. [DOI] [PubMed] [Google Scholar]
  21. Koster T., Rosendaal F. R., Briët E., van der Meer F. J., Colly L. P., Trienekens P. H., Poort S. R., Reitsma P. H., Vandenbroucke J. P. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood. 1995 May 15;85(10):2756–2761. [PubMed] [Google Scholar]
  22. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  23. Lane D. A., Olds R. J., Boisclair M., Chowdhury V., Thein S. L., Cooper D. N., Blajchman M., Perry D., Emmerich J., Aiach M. Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993 Aug 2;70(2):361–369. [PubMed] [Google Scholar]
  24. Lane D. A., Olds R. J., Conard J., Boisclair M., Bock S. C., Hultin M., Abildgaard U., Ireland H., Thompson E., Sas G. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest. 1992 Dec;90(6):2422–2433. doi: 10.1172/JCI116133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Levine M. N., Hirsh J., Gent M., Turpie A. G., Weitz J., Ginsberg J., Geerts W., LeClerc J., Neemeh J., Powers P. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995 Aug;74(2):606–611. [PubMed] [Google Scholar]
  26. Lijnen H. R., Hoylaerts M., Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem. 1980 Nov 10;255(21):10214–10222. [PubMed] [Google Scholar]
  27. Mahasandana C., Suvatte V., Marlar R. A., Manco-Johnson M. J., Jacobson L. J., Hathaway W. E. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet. 1990 Jan 6;335(8680):61–62. doi: 10.1016/0140-6736(90)90201-f. [DOI] [PubMed] [Google Scholar]
  28. Miletich J., Sherman L., Broze G., Jr Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987 Oct 15;317(16):991–996. doi: 10.1056/NEJM198710153171604. [DOI] [PubMed] [Google Scholar]
  29. Ohlin A. K., Marlar R. A. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood. 1995 Jan 15;85(2):330–336. [PubMed] [Google Scholar]
  30. Olds R. J., Lane D. A., Chowdhury V., Sas G., Pabinger I., Auberger K., Thein S. L. (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations. Hum Mutat. 1994;4(1):31–41. doi: 10.1002/humu.1380040105. [DOI] [PubMed] [Google Scholar]
  31. Raschke R. A., Reilly B. M., Guidry J. R., Fontana J. R., Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993 Nov 1;119(9):874–881. doi: 10.7326/0003-4819-119-9-199311010-00002. [DOI] [PubMed] [Google Scholar]
  32. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 1995 Oct 28;346(8983):1133–1134. doi: 10.1016/s0140-6736(95)91803-5. [DOI] [PubMed] [Google Scholar]
  33. Reitsma P. H., Ploos van Amstel H. K., Bertina R. M. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. J Clin Invest. 1994 Feb;93(2):486–492. doi: 10.1172/JCI116997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  35. Rosendaal F. R., Koster T., Vandenbroucke J. P., Reitsma P. H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995 Mar 15;85(6):1504–1508. [PubMed] [Google Scholar]
  36. Schramm W., Spannagl M., Bauer K. A., Rosenberg R. D., Birkner B., Linnau Y., Schwarz H. P. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun;129(6):753–756. [PubMed] [Google Scholar]
  37. Schulman S., Rhedin A. S., Lindmarker P., Carlsson A., Lärfars G., Nicol P., Loogna E., Svensson E., Ljungberg B., Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995 Jun 22;332(25):1661–1665. doi: 10.1056/NEJM199506223322501. [DOI] [PubMed] [Google Scholar]
  38. Schwartz R. S., Bauer K. A., Rosenberg R. D., Kavanaugh E. J., Davies D. C., Bogdanoff D. A. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med. 1989 Sep 11;87(3B):53S–60S. doi: 10.1016/0002-9343(89)80533-9. [DOI] [PubMed] [Google Scholar]
  39. Shen L., Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994 Jul 22;269(29):18735–18738. [PubMed] [Google Scholar]
  40. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  41. Tabernero M. D., Tomas J. F., Alberca I., Orfao A., Lopez Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991 Apr;36(4):249–254. doi: 10.1002/ajh.2830360405. [DOI] [PubMed] [Google Scholar]
  42. Tait R. C., Walker I. D., Reitsma P. H., Islam S. I., McCall F., Poort S. R., Conkie J. A., Bertina R. M. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995 Jan;73(1):87–93. [PubMed] [Google Scholar]
  43. Tripodi A., Franchi F., Krachmalnicoff A., Mannucci P. M. Asymptomatic homozygous protein C deficiency. Acta Haematol. 1990;83(3):152–155. doi: 10.1159/000205194. [DOI] [PubMed] [Google Scholar]
  44. Viganò S., Mannucci P. M., Solinas S., Bottasso B., Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol. 1984 Jun;57(2):213–220. [PubMed] [Google Scholar]
  45. Voorberg J., Roelse J., Koopman R., Büller H., Berends F., ten Cate J. W., Mertens K., van Mourik J. A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994 Jun 18;343(8912):1535–1536. doi: 10.1016/s0140-6736(94)92939-4. [DOI] [PubMed] [Google Scholar]
  46. Yuen P., Cheung A., Lin H. J., Ho F., Mimuro J., Yoshida N., Aoki N. Purpura fulminans in a Chinese boy with congenital protein C deficiency. Pediatrics. 1986 May;77(5):670–676. [PubMed] [Google Scholar]
  47. Zöller B., Svensson P. J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994 Dec;94(6):2521–2524. doi: 10.1172/JCI117623. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES